I guess in some things, I would say, for opportunistic salpingectomy, we're actually the global leaders. The statistics and uptakes on that are fantastic.
Prevention or screening is difficult anywhere in ovarian cancer. I would say that we all globally struggle. There are different models of population-based testing in other countries that I think are good examples and that I hope we move toward, and there's the risk-based assessment that Dr. Hanley touched on. I think some countries have better vaccination rates than we do that could be learned from. Some are worse.
I'll let others comment, but I don't think there's one country that's an example. I would say the defeating thing is that this lack of funding in gynecologic cancers is international, unfortunately.